Drugs / MEDI-570
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02520791 | Sep 2016 → Dec 2024 overdue | B-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01127321 | May 2010 → Jul 2012 | systemic lupus erythematosus | MedImmune LLC | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | AstraZeneca | Results AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020 astrazeneca.com ↗
Phase I data from the anti-inducible co-stimulator anti-ICOS monoclonal antibody, MEDI-570, demonstrating promising early clinical activity in poor-risk refractory and heavily pre-treated patients with angioimmunoblastic T-cell lymphoma |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | AstraZeneca | AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020 astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01127321 ↗ |
| Action | Deplete | “MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models.” PMID 36826995 ↗ May 2023 |
| Modality | Monoclonal antibody | “MEDI-570 is a monoclonal antibody against ICOS” PMID 36826995 ↗ May 2023 |
| Route | Subcutaneous | “subcutaneous injection” NCT01127321 ↗ |
| Target | ICOS | “MEDI-570 is a monoclonal antibody against ICOS” PMID 36826995 ↗ May 2023 |